Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Merck
Argus Health
Covington
Express Scripts
US Department of Justice
Federal Trade Commission
Chinese Patent Office
Chubb

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,525,060

« Back to Dashboard

Summary for Patent: 6,525,060
Title: Triazolo(4,5-d)pyrimidine compounds
Abstract:Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: ##STR1## wherein R, X and R.sup.1 through R.sup.3 are as defined in the specification.
Inventor(s): Hardern; David (Sutton Bonington, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (West Bridgford, GB), Guile; Simon (Loughborough, GB)
Assignee: Astrazeneca UK Limited (London, GB)
Application Number:09/508,195
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,525,060
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,525,060

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y Y TREATMENT OF POST-MYOCARDIAL INFARCTION ➤ Try a Free Trial
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y Y TREATMENT OF STROKE ➤ Try a Free Trial
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y Y REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME ➤ Try a Free Trial
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y Y REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,525,060

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9804211Dec 04, 1998
Sweden9901271Apr 09, 1999
PCT Information
PCT FiledDecember 02, 1999PCT Application Number:PCT/SE99/02256
PCT Publication Date:June 15, 2000PCT Publication Number: WO00/34283

Non-Orange Book US Patents Family Members for Patent 6,525,060

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE46276 Triazolo(4,5-D)pyrimidine compounds ➤ Try a Free Trial
6,974,868 Compounds ➤ Try a Free Trial
7,250,419 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,525,060

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I229674 ➤ Try a Free Trial
Turkey 200101567 ➤ Try a Free Trial
Slovakia 286007 ➤ Try a Free Trial
Slovakia 7492001 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Queensland Health
Julphar
Deloitte
Express Scripts
UBS
AstraZeneca
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.